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Human lung mast cells (HLMC) express the Ca
2+-activated K
+ channel KCa3.1, which
opens following IgE-dependent activation. This hyperpolarises the cell membrane and
potentiates both Ca
2+ influx and degranulation. In addition, blockade of KCa3.1
profoundly inhibits HLMC migration to a variety of diverse chemotactic stimuli. KCa3.1
activation is attenuated by the b2adrenoceptor through a Gas-coupled mechanism
independent of cyclic AMP. Adenosine is an important mediator that both attenuates
and enhances HLMC mediator release through the Gas-coupled A2A and A2B adenosine
receptors, respectively. We show that at concentrations that inhibit HLMC degranula-
tion (10
–5–10
–3 M), adenosine closes KCa3.1 both dose-dependently and reversibly.
KCa3.1 suppression by adenosine was reversed partially by the selective adenosine A2A
receptor antagonist ZM241385 but not by the A2B receptor antagonist MRS1754, and
the effectsof adenosine were mimickedbythe selective A2A receptor agonist CGS21680.
Adenosine also opened a depolarising current carried by non-selective cations. As
predicted from the role of KCa3.1 in HLMC migration, adenosine abolished HLMC
chemotaxis to asthmatic airway smooth muscle-conditioned medium. In summary, the
Gas-coupled adenosine A2A receptor closes KCa3.1, providing a clearly defined
mechanism by which adenosine inhibits HLMC migration and degranulation. A2A
receptor agonists with channel-modulating function may be useful for the treatment of
mast cell-mediated disease.
Introduction
Mast cells are bone marrow-derived cells that are
present in all organs throughout the human body, both
at mucosal surfaces and within connective tissues. Mast
cells play a major role in tissue homeostasis, host
defence and the pathophysiology of many diverse
diseases [1]. They are best known for their role in
asthma and allergy through the ability of allergen to
cross-link allergen-specific IgE bound to the high-
affinity IgE receptor (FceRI) expressed on the mast cell
surface [2, 3]. FceRI cross-linking triggers a complex
signalling cascade, which culminates in the influx of
extracellular Ca
2+ and the release of a plethora of
autacoid mediators, proteases and cytokines [1]. In
addition, the mast cell is activated by many non-
immunologicalstimulisuchascytokines[4],Igfreelight
chains[5], Toll-likereceptorligands [6–8]andproteases
[9], which contribute to the activation of mast cells in
response to a variety of tissue insults. In many diseases
mast cells re-locate to specific compartments within
tissue, such as the airway smooth muscle [10] and
submucosal glands [11] in asthma.Drugs that target this
migration may prove particularly effective in the
treatment of mast cell-mediated disease.
Ion channels are emerging as interesting targets for
the modulation of biological function in both inflam-
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Following FceRI cross-linking, human lung mast cells
(HLMC) open the intermediate conductance Ca
2+-
activated K
+ channel KCa3.1 (also known as IKCa1/
KCa4),whichhyperpolarisesthecellmembranepotential
to around –45 mV [14]. The negative cell membrane
potentialgenerated bytheseopen K
+channels enhances
HLMC Ca
2+ influx and histamine release [14,15] due to
boththefavourableelectricaldrivingforceforCa
2+entry
andenhancedCa
2+conductancethroughstore-operated
Ca
2+ channels that mediate Ca
2+ influx following cell
activation [16]. Also of great interest, blockade of KCa3.1
virtually abolishes HLMC migration to a number of
diverse chemotactic stimuli including asthmatic airway
smooth muscle-conditioned medium [17].
KCa3.1 in HLMC is closed by the b2-adrenoceptor
agonist salbutamol [18]. This occurs through a Gas G
protein-coupled mechanism that is independent of
cAMP and explains in part how b2-adrenoceptor
stimulation translates into reduced secretion. Whether
this is specific to the b2-adrenoceptor or whether KCa3.1
is modulated by other G protein-coupled receptors
(GPCR) is therefore of great interest. Adenosine is a
purine nucleoside generated by numerous cell types in
response to cell stress and hypoxia. It modulates human
mast cell secretion through the adenosine A2A and A2B
GPCR and is of particular relevance to asthma [19–21].
The A2A receptor signals via adenylate cyclase, involving
Gas coupling, and A2B signals via multiple mechanisms
including adenylate cyclase, diacylglycerol and inositol
triphosphate, involving both Gas and Gaq coupling [22].
A2B signalling has additionally been show to be
mediated independently of G proteins via PDZ-contain-
ing proteins. The effects of adenosine on HLMC both in
vitro and in vivo are complex; at relatively low
concentrations in vitro (10
–6 M), adenosine is said to
potentiate IgE-dependent secretion, but the reported
effects vary widely [23–27]. Because adenosine induces
cytokine secretion from a human mast cell line through
theA2B receptor [28], it is also thought that potentiation
ofsecretionfrom HLMC ismediated viatheA2Breceptor,
but this is not proven. In contrast, at higher concentra-
tions of adenosine (10
–5 to 10
–3 M), there is more
consistent dose-dependent and profound inhibition of
secretion [23, 24, 27, 29], mediated predominantly via
the A2A receptor [30]. In vivo, adenosine induces
histamine and tryptase release from resident mast cells
when delivered as an aerosol to the airways [31] and
induces bronchoconstriction in subjects with asthma but
not normal subjects. It is thought that these in vivo
effects are mediated directly on mast cells, although it
remains possible that intermediaries and neural reflexes
are also involved [32].
SinceKCa3.1inHLMCisclosedbytheGas-coupledb2-
adrenoceptor, wehypothesisedthat activationof the A2A
Gas-coupled adenosine receptor would also close KCa3.1
in these cells. Furthermore, if adenosine was to close
KCa3.1, then it should inhibit HLMC chemotaxis. To test
this hypothesis, we used the patch-clamp technique to
investigate the effects of adenosine on HLMC ion
channel function and investigated the effect of adeno-
sine onHLMC migrationinresponsetoasthmaticairway
smooth muscle-conditioned medium.
Results
Inhibition of HLMC IgE-dependent histamine
release by adenosine
Adenosine alone had no effect on mast cell histamine
releaseinthedoserange10
–10to10
–3 M (Fig.1A).Inthe
presence of anti-IgE, no potentiation of IgE-dependent
histamine release by adenosine was evident with either
maximal (1:1000 anti-IgE) or sub-maximal (1:30 000
anti-IgE) activation (Fig. 1B). However, there was dose-
dependent inhibition of IgE-dependent histamine re-
lease over the dose range 10
–6 to 10
–3 M adenosine
(Fig.1B). Half-maximal suppression (IC50) of histamine
release occurred at an adenosine concentration of
73.823.5 lM. This inhibition of histamine release by
adenosine was significantly attenuated in the presence
of the adenosine A2A receptor antagonist ZM241385
(Fig. 1C).
Adenosine alone does not open KCa3.1 but opens
an outwardly rectifying non-selective cation
current
Adenosine at around 10
–6 M has been reported to
enhance IgE-dependent histamine release, although this
was not the case in our hands. We therefore first
examined the effects of adenosine alone in the
concentration range 10
–7 to 10
–3 M to assess whether
it might open KCa3.1, but it did not. However, adenosine
at 10
–4 and 10
–3 M did open a novel strongly outwardly
rectifying current (Fig. 2A). With an adenosine
concentration of 10
–3 M, this current appeared in 15/
18 cells tested (n=6 donors) within 30 s of adding
adenosine to the recording chamber, consistently
reached maximal amplitude over the course of a few
seconds, and typically “ran-down” completely over 20 s.
This sequence could be re-initiated on further applica-
tion of adenosine, but thetransient nature of the current
prevented detailed electrophysiological characterisa-
tion. In cells in which the outward current appeared,
adenosine at a concentration of 10
–3 M increased
membrane current measured at +100 mV from
13.03.4 pA to 153.027.0 pA (n=15), with a positive
shift in reversal potential from –14.43.4 mV to
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aneous activation following voltage steps and increased
slightly in amplitude over the course of a 100-milli-
second pulse (Fig. 2B). There was no significant change
in reversal potential or mean current at +100 mV when
recording with extracellular Na
+ methanesulphonate
(162.262.1 pA, n=4, p=0.89) or N-methyl-D-gluca-
mine (NMDG) Cl
– (18048.2 pA, n=7, p=0.61) rather
than NaCl, and there was no change when recording
with intracellular Cs
2+ glutamate (142.036.3 pA,
n=4, p=0.928) rather than KCl. However, replacing
intracellular K
+ with N-methyl-D-glucamine markedly
reducedtheoutwardcurrentat+100 mV(31.76.0 pA,
n=6, p=0.0013) but did not alter the reversal potential
(Vm 5.83.5 mV, p=0.99). The ions carried by this
current are therefore non-selective cations. Lastly, the
selective adenosine A2A receptor agonist CGS21680 did
not induce this outward current, and the current was
still inducible in the presence of the selective A2A and
A2B receptor antagonists ZM241385 [33]
(120.652.6 pA at +100 mV, n=5, p=0.56) and
MRS1754 [34] (160.266.9 pA at +100 mV, n=5,
p=0.91), respectively. Taken together this suggests that
induction of this non-selective cation current does not
involve the A2A or A2B adenosine receptors.
Figure1.EffectsofadenosineonhistaminereleasefromHLMC.
(A) Effect of adenosine on constitutive histamine release from
HLMC. The mean  SEM of four experiments is shown. (B)
Effect of adenosine on IgE-dependent histamine release from
HLMC following a maximal (1:1000 anti-IgE) or submaximal
(1:30 000 anti-IgE) activation stimulus. The mean  SEM of four
experiments is shown (*p<0.05 compared to control). (C)
Inhibition of histamine release by adenosine is attenuated
by the adenosine A2A receptor antagonist ZM241385. The mean
 SEM of four experiments is shown. Donors are different from
those in (A) and (B).
Figure 2. Adenosine activates an outwardly rectifying non-
selective cation current in HLMC. (A) Current-voltage curve of
the outwardly rectifying current induced by 10
–3 M adenosine
in a resting HLMC. (B) Raw current from the same cell as in (A)
demonstrating instantaneous activation following voltage
steps and slight accentuation during a 100 millisecond pulse.
The voltage protocol is shown inset.
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specific KCa3.1 opener 1-EBIO
We next examined whether adenosine closes KCa3.1 at
concentrations that inhibit IgE-dependent degranula-
tion. Because adenosine might potentially inhibit many
cell activation pathways that could reduce cytosolic free
Ca
2+ and thus reduce KCa3.1 activity indirectly, we
concentrated on studying the effects of adenosine on
KCa3.1 currents that were induced by the KCa3.1 opener
1-ethyl-2-benzimidazolinone (1-EBIO). This compound
opens KCa3.1 with a half-maximal value of about 30 lM
for heterologously expressed KCa3.1, with a maximal
effect at about 300 lM [35]. The effects of 1-EBIO are
relatively specific for KCa3.1, opening it by enhancing its
sensitivity to [Ca
2+]i [35]. Thus at 100 lM 1-EBIO,
maximal K
+ currents are achieved in the presence of
100 nM free Ca
2+, which is below the resting [Ca
2+]i of
most cell types, including HLMC [15].
At concentrations of 10
–6 M and below, adenosine
had little or no effect on KCa3.1 currents that had been
activated by 1-EBIO. However, addition of adenosine
(10
–5 to 10
–3 M) to cells in which KCa3.1 had been
activated by 1-EBIO produced a rapid dose-responsive
inhibition of channel activity with an associated positive
shift in membrane potential (Fig. 3A). Adenosine at
10
–4 M suppressed the KCa3.1 current in >90% of cells
(Fig. 4A). Thus addition of 10
–4 M adenosine reduced
KCa3.1 membrane current at +40 mV from 169.316.1
to 84.812.6 pA (n=49 cells, p<0.0001)(Fig. 4A), with
a corresponding shift in reversal potential (Vm) from
61.01.3 to 35.14.0 mV (p<0.0001) (Fig. 4B). The
IC50 of KCa3.1 by adenosine occurred at 30.912.7 lM
(calculated from 5 cells). Importantly, the effect of
adenosine was partially reversed within 1 min by
removing it from the recording solution (current post-
adenosine 9041 pA, post-wash 13139 pA, n=7,
p=0.035; Vm post-adenosine 34.07.3 mV, post-wash
405.5 mV, p=0.095) (Figure 3B, C and 4C, D),
indicating that non-specific “run-down” was not re-
sponsible for the effects seen. Because the outwardly
rectifyingcurrentdescribedaboverapidlyfaded,thisdid
not interfere with analysis of the KCa3.1 current.
KCa3.1 modulation by adenosine is mediated via
A2A but not A2B receptors
To confirm that the effects of adenosine were mediated
via adenosine receptors, we examined the effects of A2A
andA2Breceptorsagonists/antagonists.Thesuppression
of KCa3.1 by adenosine was partially reversed by the
competitive A2A receptor antagonist ZM241385
(Fig. 5A–C). Thus in experiments studying ZM241385
at a concentration of 10
–6 M, current at +40 mV was
32.512.2 pA post-adenosine, increasing to
83.424.4 pA post-ZM241385 (p=0.048, n=11
cells)(Fig. 5B). There were parallel shifts in reversal
potential (Vm post-adenosine 22.310.1 mV, post-
ZM241385 39.58.4 mV, p=0.007) (Fig. 5C). How-
ever, unlike the b2-adrenoceptor inverse agonist ICI
118551 [18], ZM241385 did not open KCa3.1 on its own
(data not shown, n=10 cells tested). The effects of
adenosine on the KCa3.1 current were not mediated via
the A2B receptor, as the selective A2B receptor antagonist
MRS1754 (up to 10
–6 M) did not reverse the suppressive
effectsof adenosine (infact therewas afurthersmallbut
Figure 3. Adenosine closes KCa3.1 in HLMC. Current-voltage curves demonstrating (A) dose-dependent suppression of 1-EBIO-
induced KCa3.1 current by adenosine and (B) reversibility of adenosine-mediated suppression of KCa3.1 following removal of
adenosine (wash). (C) Raw currents from the same cell as illustrated in (B) above.
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When comparing the effects of ZM241385 with
MRS1754 regarding their ability to reverse the adeno-
sine-suppressed KCa3.1 current, there was a highly
significant difference (p=0.008).
In further support of the A2A adenosine receptor
coupling to the KCa3.1 channel, the selective A2A
receptor agonist CGS21680 mimicked the effects of
native adenosine in a dose-dependent and partially
reversible manner (Fig.6). At aconcentration of 10
–6 M,
CGS21680 reduced the KCa3.1 current from
118.824.1 pA to 97.421.8 pA (p=0.007, n=9).
Lastly, we confirmed that the adenosine-dependent
regulation of KCa3.1was relevanttoKCa3.1 channels that
had been opened by anti-IgE-dependent activation.
Anti-IgE (1:1000 dilution) opened KCa3.1 in 6/6 cells
tested (baseline current at +40 mV 17.57.3 pA, base-
line Vm 34.58.0 mV; post anti-IgE current
81.518.0 pA, Vm 62.32.5 mV). Adenosine
(10
–4 M) suppressed the current to 49.312.6 pA
post-adenosine (p=0.007) and produced an associated
positive shift in Vm (49.26.5 mV, p=0.046). This
suppressive effectof adenosine was partially reversed by
ZM241385 (current 75.619.8 pA, p=0.050; Vm
58.54.8 mV, p=0.020)(Fig. 7).
Adenosine inhibits HLMC migration
Conditioned medium from asthmatic airway smooth
muscle that has been activated with TNF-a, IFN-c and
IL-1b mediates HLMC chemotaxis predominantly via the
CXCL10/CXCR3 pathway, with additional contributions
from ligands for CXCR1 and CXCR3 [36]. Inhibition of
KCa3.1 by channel blockers markedly suppresses this
HLMC chemotaxis [17]. Migration of HLMC using
conditioned medium from asthmatic airway smooth
muscle was 2.00.7-fold higher than in the presence of
control medium (n=5, p=0.029), and this was almost
completely abrogated by adenosine, with a calculated
IC50 of 2.50.8 lM (Fig. 8A). This inhibitory effect of
adenosine on HLMC migration utilised the A2A adeno-
sine receptor, as it was blocked by the A2A receptor
antagonist ZM241385 (10
–6 M) (n=3, p=0.010)
(Fig. 8B).
Discussion
In this study we have tested the novel hypothesis that
modulation of HLMC activation by adenosine interferes
with ion channel function in these cells. We show for the
firsttimethatadenosineclosestheKCa3.1K
+channelvia
the Gas-coupled A2A adenosine receptor and that, as
predicted from this effect, adenosine markedly attenu-
ates HLMC migration. Since opening of the KCa3.1 K
+
channel potentiates Ca
2+ influx and histamine secretion
[14] and its blockade almost abolishes chemotactic
responses [17], the ability of adenosine to close this
channel provides a potential mechanism directly linking
A2A receptor engagement with diminished secretion and
migration.
Adenosine closed KCa3.1 following IgE-dependent
activation,butitwaspossiblethatthiseffectmightoccur
indirectly through the perturbation of complex intra-
cellular signalling pathways. We therefore used the
Figure 4. Suppression of KCa3.1 by adenosine is consistent and
reversible. (A) Suppression of KCa3.1 current measured at
+40 mV by 10
–4 M adenosine (n=49 cells). (B) Shift in whole-cell
current reversal potential (Vm) by 10
–4 M adenosine (n=49
cells). (C) KCa3.1 current measured at +40 mV after addition of
1-EBIO, suppression by 10
–4 M adenosine and then reversibility
of suppression following removal of adenosine (wash) (n=7
cells). (D) Whole-cell current reversal potential (Vm) after the
addition of 1-EBIO, a depolarising positive shift in response to
10
–4 M adenosine and then reversibility following removal of
adenosine (wash) (n=7 cells).
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IgE-dependent activation. Since 1-EBIO opens KCa3.1 in
resting cells by increasing its affinity for Ca
2+ [35], it is
particularly interesting that adenosine closes KCa3.1
under these conditions. This effect of adenosine was
reversedbothbyremovingitfromtherecordingsolution
and by the addition of the competitive A2A adenosine
receptor antagonist ZM241385, indicating a receptor-
mediated mechanism. Since the effects of adenosine
were not antagonised by the A2B receptor antagonist
MRS1754 but were mimicked by the A2A receptor
agonist CGS21680, we have firm evidence that the
suppression of KCa3.1 by adenosine is mediated via the
A2A adenosine receptor.
The ability of adenosine to close KCa3.1 is in keeping
with our previous observations that this channel is
closed by the Gas-coupled b2-adrenoceptor [18]. These
effects of both A2A adenosine and b2-adrenoceptor
activation on KCa3.1 are not mimicked by cAMP
analogues or the activator of adenylate cyclase forskolin
[18], indicating that the most likely mechanism is
membrane-delimited involving the Gas or bc subunits of
these GPCR. This is further suggested by the fact that
adenosine (and b2-receptor agonists) modulate KCa3.1
in the whole-cell configuration of patch-clamp record-
ing. This mode of recording dialyses the cell and
depletes soluble intracellular second messengers, in-
dicating that the adenosine A2A receptor and KCa3.1
channel are likely to be coupled tightly in a membrane-
restricted signalplex.
Several molecules that attenuate HLMC secretion,
including adenosine and b2-adrenoceptor agonists,
increase intracellular cAMP. It is this increase in
intracellular cAMP that has been thought to couple to
inhibition of secretion, but there is no mechanism to
explain this. However, the exclusive role of cAMP in the
inhibition of mast cell degranulation and promotion of
smooth muscle relaxation has recently been challenged
[37, 38]. We have shown previously that opening of
KCa3.1 enhances IgE-dependent Ca
2+ influx and degra-
nulation [15] and that its blockade attenuates this [14].
Thus the demonstration that adenosine closes KCa3.1
provides for the first time a clearly defined mechanism
by which adenosine A2A receptor stimulation can be
linked to attenuated secretion.
·
Figure 5. Effects of adenosine receptor antagonists on
adenosine-dependent closure of KCa3.1. (A) Current-voltage
curve demonstrating the reversibility of KCa3.1 suppression of
adenosine by the A2A receptor antagonist ZM241385. (B) KCa3.1
current measured at +40 mVafter addition of 1-EBIO, suppres-
sion by 10
–4 M adenosine and then reversibility of suppression
following addition of the A2A receptor antagonist ZM241385
(n=11 cells). (C) Whole-cell current reversal potential (Vm) after
the addition of 1-EBIO, a depolarising positive shift in response
to 10
–4 M adenosine, and then reversibility following addition
of the A2A receptor antagonist ZM241385 (n=11 cells). (D) KCa3.1
current measured at +40 mVafter addition of 1-EBIO, suppres-
sion by 10
–4 M adenosine and then failure to reverse following
additionofthe A2BreceptorantagonistMRS1754(n=17cells).(E)
Whole-cell current reversal potential (Vm) after the addition of
1-EBIO, a depolarising positive shift in response to adenosine
and then failure to reverse following addition of the A2B
receptor antagonist MRS1754 (n=17 cells).
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tissues is important for their effector function in a
number of diseases [10, 39, 40]. For example in asthma,
theroleofmastcellsinthedisorderedairwayphysiology
is facilitated by their migration into the airway
epithelium [41], submucosal glands [11] and airway
smooth muscle [10]. Inhibition of their migration and
subsequent microlocalisation within these structures is
therefore an attractive therapeutic target. Blockade of
KCa3.1 markedly inhibits HLMC migration in response to
a number of diverse chemotactic stimuli, including
conditioned medium from activated asthmatic airway
smooth muscle [17]. The ability of adenosine to close
KCa3.1 suggested it should also inhibit HLMC migration,
which was indeed the case. Adenosine was slightly more
potent at inhibiting migration (IC50 *3 lM) than
closing KCa3.1 (IC50 *31 lM) or inhibiting mediator
release (IC50 *74 lM). These results regarding migra-
tion versus degranulation are consistent with the
observation that HLMC migration is also far more
sensitive to direct KCa3.1 blockade than degranulation
[14, 17]. Migration appears particularly sensitive to
KCa3.1 blockade, because even a partial block markedly
inhibits oscillations in KCa activity, which in turn
prevents the changes in cell volume that are required
Figure 6. The effect of an adenosine A2A receptor agonist on
KCa3.1 currents in HLMC. (A) Current-voltage curve demon-
strating dose-dependent suppression of a 1-EBIO-induced
KCa3.1 current by the A2A receptor agonist CGS21680 and (B)
reversibility of this suppression following its removal (wash).
Figure 7. The effect of adenosine on KCa3.1 currents elicited by
anti-IgE-dependent mast cell activation. Data from a repre-
sentative HLMC showing KCa3.1 current opening following
anti-IgE-dependent activation, suppression of this by adeno-
sine and reversal of the adenosine-induced suppression by the
adenosine A2A receptor antagonist ZM241385.
Figure 8. Inhibition of HLMC chemotaxis by adenosine. (A)
Conditioned medium from asthmatic airway smooth muscle
(ASM) was used as the chemotactic stimulus. Data represents
the mean  SEM from five individual HLMC donors (*p<0.005).
(B) Inhibition of HLMC migration by adenosine is prevented by
the A2A receptor antagonist ZM241385. Data represents the
mean  SEM from three individual HLMC donors.
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supported by the observation that in addition to
blocking of KCa3.1, permanently opening it with 1-EBIO
also inhibits migration [44]. However, the relative
sensitivity of migration to adenosine versus KCa3.1
closure might also suggest that the effects of adenosine
on migration operate through additional mechanisms,
such as generation of cAMP. However, the experimental
conditions are also likely to account for some of this
difference. This is because we can only reliably patch-
clampHLMCattemperaturesupto27
C[14],whichwill
likely slow down the kinetics and magnitude of any
agonist effect, and we have also recorded currents in the
whole-cell configuration, which dialyses the cell,
resulting in the loss of potentially important signalling
components. In contrast, cell migration and mediator
release assays are performed in intact cells at 37
C.
Previous studies have suggested that at lower
concentrations (approximately 10
–6 M), adenosine ac-
tually promotes mediator release from human mast cells
[23–27]. However, the magnitude of this effect and the
concentrations of adenosine required to produce it have
been highly varied [23–27, 29], and a recent study
investigating cord blood-derived human mast cells did
not find any potentiating effect [30]. Adenosine did not
potentiate degranulation from HLMC in our hands,
which is in keeping with a failure to detect any
modulation of ion channel activity, such as opening of
KCa3.1 either directly or indirectly through initiation of
Ca
2+ influx, which might be predicted to enhance
secretion. Interestingly, in rodent mast cells, adenosine
opens an outwardly rectifying K
+ channel that is not
Ca
2+-activated, is distinct from KCa3.1 and has been
proposed to account for the ability of adenosine to
enhance mediator release in these cells [45, 46]. We did
not see this channel in HLMC, which is yet another
example of the important heterogeneity evident in the
biology of human and rodent mast cells [47].
In addition to its effects on KCa3.1, adenosine at
relatively high concentrations opened a novel and
transient outwardly rectifying ion channel that was
indirectly demonstrated to carry non-selective cations.
Interestingly, this current still appeared in the presence
of the adenosine A2A and A2B receptor antagonists,
suggesting that it is mediated through another pathway.
Because this outwardly rectifying current depolarises
the cells (and would therefore be predicted to attenuate
Ca
2+ influx) and occurs at concentrations of adenosine
that attenuate degranulation, it is possible that this
channel also inhibits mast cell mediator release. The
transient nature of this current might be due to “run-
down” caused by the depletion of intracellular second
messengers induced by whole-cell recording, but we
believe that this is unlikely due to the very rapid nature
by which the current diminishes. However, it will be
important that this is analysed in more detail using the
perforated patch mode of recording.
In vivo, adenosine induces airway narrowing in
asthmatic subjects, with evidence that this results from
mastcelldegranulation[20,21].Thiseffectisthoughtto
be mediated directly via the A2B adenosine receptor on
mast cells, although this is not proven, and might also
involve indirect mechanisms [28, 32]. Adenosine A2B
receptor antagonists are therefore being considered as
novel therapies for asthma. An alternative strategy is to
target the anti-inflammatory A2A receptor with specific
agonists delivered locally to the airway [48, 49]. Drugs
that block KCa3.1 are also in development as anti-
inflammatory treatments [13]. Our demonstration that
the A2A adenosine receptor closes KCa3.1 in HLMC
therefore provides further support for the development
of specific A2A adenosine receptor agonists for the
treatment of mast cell-mediated disease.
Materials and methods
Reagents
We used the following reagents: stem cell factor (SCF), IL-6
and IL-10 (R&D, Abingdon, UK); goat polyclonal anti-human
IgE, adenosine, CGS21680, ZM241385, MRS1754 (Sigma,
Poole, Dorset, UK); 1-ethyl-2-benzimidazolinone (1-EBIO)
(Tocris, Avonmouth, UK); human myeloma IgE (Calbiochem-
Novabiochem, Nottingham, UK); mouse IgG1 mAb YB5B8
(anti-CD117) (Cambridge Bioscience, Cambridge, UK); sheep
anti-mouse IgG1 Dynabeads (Dynal, Wirral, UK); Dulbecco's
Modified Essential Medium (DMEM)/glutamax/Hepes, anti-
biotic/antimycotic solution, MEM nonessential amino acids
and FCS (Life Technologies, Paisley, Scotland, UK).
Human mast cell purification and culture
All human subjects gave written informed consent, and the
study was approved by the Leicestershire Research Ethics
Committee. HLMC were dispersed and purified from macro-
scopically normal lung (n=11 donors) obtained within 1 h of
resection for lung cancer using immunomagnetic affinity
selection as described previously [50]. Final mast cell purity
was >99%, and viability was >97%. HLMC were cultured in
DMEM/glutamax/Hepes containing antibiotic/antimycotic
solution, nonessential amino acids, 10% FCS, 100 ng/mL
SCF, 50 ng/mL IL-6 and 10 ng/mL IL-10 for up to 10 wks as
described previously [15, 51].
HLMC activation
For analysis of histamine release, 1  10
4 mast cells were
warmed to 37
C in triplicate in 50 lL DMEM. Adenosine (
ZM241385 or DMSO control) at 4 the final concentration in
25 lL DMEM was added just prior to addition of 25 lL DMEM
containing 4 the final concentration of goat polyclonal anti-
human IgE (1:1000 final dilution gives maximal histamine
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release) [15]. After 30 min incubation at 37
C, the cells were
centrifuged at 250  g for 4 min, the supernatant decanted
and control cell pellets lysed in sterile deionised water for
measurement of total histamine content as described pre-
viously [50]. The final DMSO concentration was 0.1%.
Electrophysiology
The whole-cell variant of the patch-clamp technique was used
[14, 52]. Patch pipettes were made from borosilicate fiber-
containing glass (Clark Electromedical Instruments, Reading,
UK), and their tips were heat-polished, typically resulting in
resistances of 4–6 M. The standard pipette solution con-
tained 140 mM KCl, 2 mM MgCl2, 10 mM Hepes, 2 mM Na
+-
ATP and 0.1 mM GTP, pH 7.3. The standard external solution
contained140 mMNaCl,5 mMKCl,2 mM CaCl2,1 mMMgCl2
and 10 mM Hepes, pH 7.3. For recording, mast cells were
placed in 35-mm dishes containing standard external solution.
Whole-cell currents were recorded using an Axoclamp 200 A
amplifier (Axon Instruments, Foster City, CA, USA), and
currents were evoked by applying voltage commands to a
range of potentials in 10 mV steps from a holding potential of
–20 mV. The currents were digitized (sampled at a frequency
of 10 kHz), stored on computer and subsequently analyzed
using pClamp software (Axon Instruments). Capacitance
transients were minimized using the capacitance neutraliza-
tion circuits on the amplifier. Correction for series resistance
was not routinely applied. Experiments were performed at
27
C, with the temperature controlled by a Peltier device.
Experiments were performed with a perfusion system (Auto-
mate Scientific, San Francisco, CA) to allow solution changes,
although drugs were added directly to the recording chamber.
HLMC chemotaxis
HLMC chemotaxis assays were performed using the Transwell
system (BD Biosciences, Oxford, UK) with 24-well plates as
described previously [17, 36]. Conditioned medium from
asthmatic airway smooth muscle that had been activated with
TNF-a,I L - 1 b and IFN-c was placed in the lower wells as
described previously [36], with appropriate cytokine-contain-
ing medium in the negative control. Adenosine was added to
the bottom wells in the concentration range 10
–6–10
–3 M, and
1  10
5 HLMC in 100 lL were added to the top well. After
incubating the cells for 3 h at 37
C, we counted the number of
HLMC in the bottom well using Kimura stain in a haemocyt-
ometer. HLMC migration was calculated as the fold increase of
migrated cells in the test wells compared to the negative
control (no chemoattractant in the lower well) as described
previously [17, 36].
Data presentation and statistical analysis
Data are expressed as mean  SEM unless otherwise stated.
Differences between groups of data were explored using
Student's paired or unpaired t-test (two-tailed) as appropriate.
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